TGTX

AI Memo

TG Therapeutics

As of 2026-10-22/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-22 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

—

Key catalyst

ENHANCE single-infusion dosing assessment • 2026-10-22

Base target: $62 / p=45% prob

Biggest risk

The valuation depends heavily on sustained BRIUMVI uptake, while Phase 3 subcutaneous and early azer-cel outcomes remain uncertain. Second-quarter R&D expense rose to $95.3 million from $31.8 million a year earlier, partly due to subcutaneous manufacturing and secondary-manufacturer costs. Company earnings release

Invalidation

Break below $38 or thesis failure.

What would change my mind?

BRIUMVI's 64% year-over-year second-quarter U.S. sales growth and raised 2026 target support the commercial thesis; the October 21 company update adds seven-year disease-control data and a potential simpler initiation regimen. Azer-cel and subcutaneous BRIUMVI provide distinct clinical upside, subject to readout and regulatory risk. [#SEC-8K-2026-08-03] Company clinical update

Research note

Recommendation

—

Confidence

high

As of

2026-10-22

Base target

$62

p=45%

Bull target

$76

p=30%

Bear target

$38

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

BRIUMVI sales against raised 2026 targets
Subcutaneous BRIUMVI Phase 3 readout
BRIUMVI's 64% year-over-year second-quarter U.S.

BearKey bullets

Azer-cel data are initial Phase 1 evidence; efficacy, durability, and safety in progressive MS remain unproven.
BRIUMVI carries infusion-reaction, infection, hepatitis B reactivation, and PML warnings.
Company clinical update

WatchKey bullets

ENHANCE single-infusion dosing assessment

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $62 (p=45%)

Target spread vs base: +23% / -39%

Scenario probabilities

Bull Target: $76 (p=30%)Base Target: $62 (p=45%)Bear Target: $38 (p=25%)

Commentary

Company-source tone is constructive, but the October 21 clinical update largely precedes the October 22 price-reaction window. No verified event-linked market reaction, analyst target revisions, options measure, short-interest measure, or sufficient social sample was supplied; zero-valued sentiment fields indicate unavailable data, not neutral readings. The stored earnings-document row concerns Quest Diagnostics rather than TG and was excluded.

As of 2026-10-22 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

BRIUMVI sales against raised 2026 targets
Subcutaneous BRIUMVI Phase 3 readout

Scenarios

Bull Target (Scenario probability)

$76 / p=30% prob

Base Target (Scenario probability)

$62 / p=45% prob

Bear Target (Scenario probability)

$38 / p=25% prob

Analysis 2026-10-22 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-22
ENHANCE single-infusion dosing assessment
TG reports that Phase 3 ENHANCE met its bioequivalent-exposure endpoint for a consolidated BRIUMVI initiation infusion, with comparable infusion reactions between regimens. The detailed poster is scheduled for October 22; regulatory acceptance and commercial benefit are not established. [#8-K-2026-08-03] [#PR-2026-10-21] Company release
Prob 90.00% • Move 4.00% • Priced-in 75.00%
EVENT2026-10-23
Initial azer-cel results in progressive MS
TG has scheduled an October 23 presentation of initial Phase 1 azer-cel results in progressive MS. The October 21 company release says an abstract is available, but the clinical significance of the full presentation remains uncertain. [#PR-2026-10-21] Company release
Prob 90.00% • Move 8.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

BRIUMVI sales against raised 2026 targets
2026-12-31
Second-quarter 2026 U.S. BRIUMVI net product revenue was $227.7 million, up approximately 64% year over year. TG raised its full-year U.S. product-revenue target to $890–905 million; subsequent sales must substantiate that target while development spending rises. [#8-K-2026-08-03] [#SEC-8K-2026-08-03] Company earnings release
Prob 65% • Move 7% • Priced-in 60%

Long-term Catalysts

Months to a year

Subcutaneous BRIUMVI Phase 3 readout
2027-03-31
Phase 1 bioavailability data and modeling support the quarterly subcutaneous regimen under study in a fully enrolled Phase 3 trial. TG expects topline data around year-end 2026 or the first quarter of 2027; Phase 1 pharmacokinetics do not establish Phase 3 success. [#SEC-8K-2026-08-03] Company earnings release
Prob 65% • Move 12% • Priced-in 40%

Risks

Azer-cel data are initial Phase 1 evidence; efficacy, durability, and safety in progressive MS remain unproven.
BRIUMVI carries infusion-reaction, infection, hepatitis B reactivation, and PML warnings. Company clinical update
Higher R&D and manufacturing-related spending may constrain earnings even if revenue grows. Company earnings release
Subcutaneous BRIUMVI's Phase 3 outcome and any future approval are uncertain despite supportive Phase 1 pharmacokinetics.
The ENHANCE exposure result does not itself establish regulatory approval of the proposed initiation regimen or incremental sales.

Peers

Symbol	Summary
NVS	Novartis's ofatumumab is another direct relapsing-MS treatment comparator. Novartis is much more diversified than TG, and the reported comparative findings may retain residual cross-trial confounding. Company release

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-22

Loading AI feed…

Symbol

Summary

NVS

Novartis's ofatumumab is another direct relapsing-MS treatment comparator. Novartis is much more diversified than TG, and the reported comparative findings may retain residual cross-trial confounding. Company release